Orbimed Advisors LLC Purchases 518,680 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Orbimed Advisors LLC raised its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 73.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,227,080 shares of the company’s stock after buying an additional 518,680 shares during the period. Orbimed Advisors LLC owned about 1.21% of Dyne Therapeutics worth $28,910,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. KBC Group NV raised its stake in shares of Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after acquiring an additional 978 shares during the last quarter. Summit Investment Advisors Inc. increased its holdings in Dyne Therapeutics by 9.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company’s stock valued at $203,000 after purchasing an additional 721 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in Dyne Therapeutics in the 4th quarter worth approximately $257,000. Magnetar Financial LLC purchased a new stake in Dyne Therapeutics in the 4th quarter worth approximately $263,000. Finally, E Fund Management Co. Ltd. grew its position in shares of Dyne Therapeutics by 11.8% in the 4th quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company’s stock worth $279,000 after buying an additional 1,249 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Stock Performance

DYN stock opened at $12.56 on Tuesday. The firm has a 50 day moving average price of $10.38 and a 200-day moving average price of $17.85. Dyne Therapeutics, Inc. has a 52-week low of $6.36 and a 52-week high of $47.45. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of -3.53 and a beta of 1.19.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.17). As a group, sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the completion of the transaction, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. The trade was a 1.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 6,237 shares of company stock worth $77,760 over the last three months. 14.14% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on DYN shares. HC Wainwright dropped their price target on Dyne Therapeutics from $46.00 to $38.00 and set a “buy” rating for the company in a research note on Friday. Chardan Capital restated a “buy” rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a report on Friday. Piper Sandler dropped their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. BMO Capital Markets initiated coverage on shares of Dyne Therapeutics in a research report on Wednesday, March 12th. They set an “outperform” rating and a $50.00 price target on the stock. Finally, Guggenheim reissued a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $46.85.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.